Drug Targets – Products

The SomaScan® Assay is the first and only technology that can measure 7,000 proteins over a wide range of concentrations, enabling unprecedented discovery for a variety of disease applications. The SomaScan proteomics platform supports the entire drug discovery and development pipeline from biomarker exploration to clinical trial monitoring. You can get started using the SomaScan Assay today with no set-up fees, and you maintain full ownership of your data.

Thermo Fisher Scientific and the University of California, Davis West Coast Metabolomics Center have announced The Center of Excellence in Clinical Metabolomics, a research collaboration to provide the metabolomics community with innovations, best practices and standard operating procedures to support the rapid scale-up of large cohort studies and clinical research.

Target identification and characterization are key challenges in drug discovery and begin with identifying the function of a possible therapeutic target and its role in the disease.

Download this app note to discover an automated immunoprecipitation method that offers seamless integration to protein analysis, ensures high yield and reproducibility as well as delivers low nonspecific binding with significant reductions in total and hands-on time.

Aptamer Group has announced the extension of their current agreement with AstraZeneca. This agreement will further the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates.

Dotmatics Ltd, has announced that it has entered a licensing agreement with Compugen. The multi-year agreement will provide Compugen scientists based at the Company’s R&D facility in Israel with a single information management platform.

One of the common molecular analyses is the determination of a lead molecule’s binding kinetics and affinity to the target. This warrants the need for analytical instruments capable of characterizing such molecules. Download this whitepaper to discover an approach that accurately measures multiple high-affinity interactions over long run times.

BioMed X announces the successful completion of its first joint research project with Boehringer Ingelheim in neuroscience.

Porvair Sciences reports it has agreed with its collaborative partners to make additional investment in the CEAT project.

PhoreMost Limited and Oxford Biomedica plc today announced that they have entered into a discovery collaboration to develop next-generation CAR-T cell therapies.